Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR168 in Refractory Autoimmune Disease
NCT06935474Phase 2Withdrawn
- Sponsor
- AbelZeta
- Start
- Jul 2026
- Primary completion
- May 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of C-CAR168 in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by AbelZeta. Planned start Jul 2026; status: withdrawn.
02
Drugs
C-CAR168
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06935474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935474.